Montai Therapeutics

Montai is integrating some of the most advanced computational sciences into early drug development to find and match chemical-to-biological relationships that can help identify small molecule solutions to difficult targets in chronic disease. Nathan Sanders, our Head of Data Sciences, explains the combination of expertise required to effectively pursue this challenge. #AIInnovation

This International Women’s Day, discover inspiring stories, interviews, and more from women at Flagship and?throughout?our ecosystem?of companies. Learn how they’re building and leading #FlagshipFounded?companies, driving progress for patients?and the planet, and shaping their career journeys. Read, listen, and watch as they share insights on leadership and life: https://bit.ly/41I5G7M Check out some of our recent stories featuring women in leadership at Flagship:? ???Angela Hwang reflects on her career journey from South Africa to Pfizer to Metaphore Biotechnologies: https://bit.ly/3C7IYfB ? ?????Lamya Shihabuddin, CSO of Montai Therapeutics, shares her insights on standing up for patients and progress: https://bit.ly/4hljXfb ? ???We capture?Lovisa Afzelius'?adventures and explorations in our Life Illustrated series: https://bit.ly/3ZLyc6B #IWD2025 #AccelerateAction #WeAreFlagship

Join Montai CEO?Margo Georgiadis as she meets with some of the foremost leaders in AI to discuss the opportunity for impact on the future of medicine. Catch the panel discussion next week during the #HumanX2025 conference in Las Vegas.?www.humanx.co

By applying today's most advanced AI tools, we are fueling?a pendulum shift from biologics to small molecule?solutions for some of the?most prevalent chronic inflammatory and immune-related diseases. Montai leaders Christian Antoni and?Hok Hei Tam describe how modern tools can enable this work to deliver accessible pill-based, breakthrough solutions in areas of critical need in this BioSpace?opinion piece.

The latest in the Citeline Scrip series on 2025 predictions for the biotech?industry features CMO?Dr. Christian Antoni, who adds his perspective on therapeutic momentum in immunology and the anticipated expansion of focus beyond novel modalities and toward fine-tuning pill-based solutions to address these chronic diseases. By harnessing the power of AI and digging deep into unexplored areas of chemistry, we are pursuing breakthrough solutions that can overcome the limitations of advanced biologics to enable better outcomes for large populations suffering from challenging immunological diseases.?

Today we recognize and celebrate the contributions of women and girls in science, historical and present. Montai's leadership is inspiring the next generation of female scientists and entrepreneurs to pursue passions that are making a difference in people's lives. #womeninscience #womeninSTEM?#thefutureinscience

BioSpace aptly addresses the continued need for greater female representation in biotech leadership. Montai CEO?Margo Georgiadis is featured as part of the story, sharing her experience moving from tech to biotech and her passion for mentorship to ensure women have the tools they need to thrive.

Montai's Head of Translational Medicine Adam Raff, M.D., Ph.D. shares insight?on how our platform is equipped to deliver breakthrough medicines by connecting chemistry to precise pathways that drive chronic inflammatory and autoimmune?conditions affecting people around the world.?

Montai CEO?Margo Georgiadis?joined The Nantucket Project's 2024?Gathering for a panel discussion on opportunities?for AI to promote human healing. She explains in the segment below how computational systems are the perfect tools to help sort through the millions of combinations of messages between chemistry and our human biology. Creating efficiency in the drug discovery process means we can develop breakthrough pill-based solutions to effectively treat chronic diseases that plague millions of people worldwide. Watch the discussion here:?

Montai CEO?Margo Georgiadis predicts the rise of advanced integration of AI in drug discovery in 2025 as part of Citeline's Scrip series on the biotech industry outlook for this year. This is enabled through the combination of unprecedented,?scaled access to multimodal biological and chemical data and the availability of advanced computational tools, which will make it possible to solve hard-to-drug targets with precision and selectivity. Margo and the Montai team are pioneering this integration?in pursuit of?breakthrough pill-based solutions for chronic inflammatory?and immunological diseases. #AIInnovation